FIGURE 6.

In vivo evaluation of antifungal activity of LMM5 and LMM11 compounds in murine systemic candidiasis by Candida albicans. For each compound 20 female BALB/c mice, at 6 weeks old were divided in four groups (n = 5) treated with: LMM5 (5 mg/kg), LMM11 (5 mg/kg), fluconazole (5 mg/kg) or diluent (PBS, DMSO, and 0.02% F-127). The systemic candidiasis model by C. albicans was established by administering 5 × 10⁵ yeast cells (ATCC 90028) through the lateral tail vein. After 3 h of infection, the respective treatments were administered intraperitoneally according to the group, twice a day for 5 days. (A) Colony Forming Units (Log₁₀ CFU) per g of kidney. (B) Colony Forming Units (Log₁₀ CFU) per g of spleen. The bars indicate the standard deviation. ^∗Values of p ≤ 0.05 were considered statistically significant compared with control. ^∗∗Values of p ≤ 0.05 were considered statistically significant compared with fluconazole.